Kreftgenomikk

[:no]IMPRESS NORWAY: Stor nasjonal presisjonsmedisinstudie innen kreft[:en]IMPRESS leads the way for cancer precision medicine [:]

by · Published · Updated

[:no] 

IMPRESS-Norway, en stor nasjonal studie om presisjonsmedisin mot kreft, starter på nyåret i 2021. Studien vil på grunnlag av individuelle og utvidede genanalyser gi deltakerne muligheten til å få såkalte off-label medikamenter, altså medikamenter ment for bruk i behandling av andre sykdommer, for å bekjempe akkurat deres unike kreftsykdom.
Les mer på OUS-web[:en]IMPRESS Norway is a national clinical study starting in 2021 working towards implementing cancer precision medicine in Norway.

As one of the initiators behind IMPRESS-Norway, Oslo Cancer Cluster is thrilled to see this national clinical study in cancer precision medicine become a reality.

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease, according to the National Cancer Institute. Read more at the Oslo Cancer Cluster Web Site.[:]